- 专利标题： MACROCYCLIC INDOLES AS MCL-1 INHIBITORS
-
申请号： US17047423申请日： 2019-11-20
-
公开(公告)号： US20220340595A1公开(公告)日： 2022-10-27
- 发明人: Hao Chen , Wenming Chen , Chao Li , Dongbo Li , Yu Jing , Guozhi Tang , Yunlong Zhou , Shaomeng Wang , Chao-Yie Yang
- 申请人： ASCENTAGE PHARMA (SUZHOU) CO., LTD. , THE REGENTS OF THE UNIVERSITY OF MICHIGAN , ASCENTAGE PHARMA GROUP CORP LIMITED
- 申请人地址： CN Suzhou; US MI Ann Arbor; HK Central Hong Kong
- 专利权人： ASCENTAGE PHARMA (SUZHOU) CO., LTD.,THE REGENTS OF THE UNIVERSITY OF MICHIGAN,ASCENTAGE PHARMA GROUP CORP LIMITED
- 当前专利权人： ASCENTAGE PHARMA (SUZHOU) CO., LTD.,THE REGENTS OF THE UNIVERSITY OF MICHIGAN,ASCENTAGE PHARMA GROUP CORP LIMITED
- 当前专利权人地址： CN Suzhou; US MI Ann Arbor; HK Central Hong Kong
- 优先权： CNPCT/CN2018/116988 20181122
- 国际申请： PCT/CN2019/119698 WO 20191120
- 主分类号： C07D515/22
- IPC分类号： C07D515/22 ; A61P35/00
摘要：
Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
公开/授权文献
- US11691989B2 Macrocyclic indoles as Mcl-1 inhibitors 公开/授权日：2023-07-04
信息查询
